Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLT180a Long-Term Follow-Up in Haemophilia B
NCT03641703Phase 2Terminated
- Sponsor
- Spur Therapeutics
- Start
- Jul 2018
- Primary completion
- May 2023
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of verbrinacogene setparvovec in hemophilia B (HB), sponsored by Spur Therapeutics. Started Jul 2018; status: terminated.
02
Drugs
verbrinacogene setparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on NCT03641703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641703.